A higher non-severe hypoglycaemia rate is associated with an increased risk of subsequent severe hypoglycaemia and major adverse cardiovascular events in individuals with type 2 diabetes in the LEADER study

Diabetes - GeneralType 2 Diabetes

The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial

Diabetes Care.

Dhatariya K, Bain SC, Buse JB, Simpson R, Tarnow L, Kaltoft MS, Stellfeld M, Tornøe K, Pratley RE; LEADER Publication Committee on behalf of the LEADER Trial Investigators

doi: 10.2337/dc18-1094.

Diabetes - GeneralType 2 DiabetesGlycemic Control

Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study

Diabetologia.

Penno G, Solini A, Orsi E, Bonora E, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Lamacchia O, Scardapane M, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group

doi: 10.1007/s00125-018-4691-2.

COMMENTED

Type 2 Diabetes

Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and All-Cause Mortality for Widely Used Antihyperglycemic Dual and Triple Therapies for Type 2 Diabetes Management: A Cohort Study of All Danish Users

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

doi: 10.2337/dc19-2535.

COMMENTED

Diabetes - GeneralType 2 Diabetes

Use of Vascular Assessments and Novel Biomarkers to Predict Cardiovascular Events in Type 2 Diabetes: The SUMMIT VIP Study

Diabetes Care.

Shore AC, Colhoun HM, Natali A, Palombo C, Khan F, Östling G, Aizawa K, Kennbäck C, Casanova F, Persson M, Gooding K, Gates PE, Looker H, Dove F, Belch J, Pinnola S, Venturi E, Kozakova M, Goncalves I, Kravic J, Björkbacka H, Nilsson J; SUMMIT Consortium

doi: 10.2337/dc18-0185.

COMMENTED

Diabetes - GeneralType 2 Diabetes

Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study

BMJ

Douros A, Dell'Aniello S, Yu OHY, Filion KB, Azoulay L, Suissa S

doi: 10.1136/bmj.k2693.

COMMENTED

Diabetes - GeneralType 2 Diabetes

Effect of population screening for type 2 diabetes and cardiovascular risk factors on mortality rate and cardiovascular events: a controlled trial among 1,912,392 Danish adults

Diabetologia.

Simmons RK, Griffin SJ, Witte DR, Borch-Johnsen K, Lauritzen T, Sandbæk A

doi: 10.1007/s00125-017-4323-2.

COMMENTED

Type 2 Diabetes

Higher circulating omentin is associated with increased risk of primary cardiovascular events in individuals with diabetes

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Diabetologia.

Niersmann C, Carstensen-Kirberg M, Maalmi H, Holleczek B, Roden M, Brenner H, Herder C, Schöttker B

doi: 10.1007/s00125-019-05017-2.

COMMENTED

Diabetes - GeneralType 1 DiabetesType 2 DiabetesGlycemic Control

Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia

doi: 10.1007/s00125-017-4449-2.

COMMENTED

Type 2 Diabetes

Cardiovascular safety and severe hypoglycaemia benefit of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: results from DEVOTE (DEVOTE 7)

Diabetes Obes Metab.

Pratley RE, Emerson SS, Franek E, Gilbert MP, Marso SP, McGuire DK, Pieber TR, Zinman B, Hansen CT, Hansen MV, Mark T, Moses AC, Buse JB, DEVOTE Study Group

doi: 10.1111/dom.13699.

Related content

The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial

Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study

Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and All-Cause Mortality for Widely Used Antihyperglycemic Dual and Triple Therapies for Type 2 Diabetes Management: A Cohort Study of All Danish Users

Use of Vascular Assessments and Novel Biomarkers to Predict Cardiovascular Events in Type 2 Diabetes: The SUMMIT VIP Study

Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study

Effect of population screening for type 2 diabetes and cardiovascular risk factors on mortality rate and cardiovascular events: a controlled trial among 1,912,392 Danish adults

Higher circulating omentin is associated with increased risk of primary cardiovascular events in individuals with diabetes

Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia

Cardiovascular safety and severe hypoglycaemia benefit of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: results from DEVOTE (DEVOTE 7)